News

The subcutaneous version of the cancer treatment atezolizumab is approved in all adult intravenous indications, including in lung, liver, and skin cancers.

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.

The investigational new drug application for VNX-101, a gene therapy aimed at treating CD19-positive acute lymphoblastic leukemia, has been approved by the FDA.

The phase 3 Shorespan-007 trial will compare bomedemstat with hydroxyurea in patients with treatment-naive essential thrombocythemia.

Alessandra Ferrajoli, MD, discusses the session she was a part of at the 2024 Society of Hematologic Oncology Annual Meeting.

Findings from a real-world study showed that zanubrutinib was associated with lower rates of treatment switching and patients receiving subsequent therapy compared with acalabrutinib and ibrutinib in patients with CLL or SLL.

The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.

The digital twin trial arm demonstrated a 52.7% overall response rate at 6 months for prednisone in chronic GVHD, aligning with real-world data.

Tebapivat, a novel pyruvate kinase activator, is being investigated for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.

HER2DX has shown a strong association between ERBB2 mRNA and survival in patients with HER2-positive breast cancer.

The investigational agent certepetide has been granted FDA orphan drug designation for the treatment of patients with cholangiocarcinoma.

The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.

In this preview, we highlight the key late-breaking abstracts to be presented at the 2024 ESMO Congress across various tumor types that may impact clinical practice.

Pretreatment with dexamethasone significantly reduced infusion-related reactions in patients receiving amivantamab for advanced lung cancer, according to findings from the SKIPPirr study.

The trial previously met its primary end point of progression-free survival, and the final overall survival analysis was recently presented at the 2024 World Conference on Lung Cancer.

Breast cancer diagnostics, therapeutics, and biomarker-driven therapy will be important focal points during the 22nd Annual School of Breast Oncology conference.

The next-generation radiopharmaceutical ABD-147 was previously granted FDA fast track designation in extensive-stage small cell lung cancer.

The bispecific T-cell engager tarlatamab showed continued efficacy and tolerable safety, according to follow-up from the phase 2 DeLLphi-301 study.

Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for at the upcoming ESMO Congress in Barcelona, with some additional tidbits to round out the main event.

Golcadomide plus R-CHOP was well tolerated and demonstrated high metabolic response rates that were durable in patients with previously untreated a-BCL.

As oncologists and the healthcare industry advance their practices to propel care for children, it is crucial for the industry and population at large to tailor care for the unique needs of children to maximize recovery and truly help patients thrive.

In FRα-positive, platinum-resistant ovarian cancer, mirvetuximab soravtansine showed improvements in progression-free survival, overall response rate, and overall survival.

Subcutaneous and intravenous forms of rituximab showed similar efficacy in patients with non-Hodgkin lymphoma.

Anil Parwani, MD, PhD, addresses potential biases or limitations in the artificial intelligence algorithm used at his institution.

The novel agent VMT01 is designed to target and deliver 212Pb to MC1R-expressing tumors like metastatic melanoma.

Ifinatamab deruxtecan, a novel antibody-drug conjugate, returned promising response rates at both dose levels evaluated among patients with small cell lung cancer.

Denileukin diftitox, an IL-2-receptor-directed cytotoxin, has been added to the NCCN guidelines for the treatment of adult patients with cutaneous T-cell lymphoma.

Valemetostat showed promise as a treatment option for patients with relapsed/refractory peripheral T-cell lymphoma.

Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus concurrent chemoradiotherapy for patients with high-risk, locally advanced cervical cancer in the East Asia subgroup of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.

The combination of durvalumab, chemotherapy, and bevacizumab, followed by maintenance with olaparib, durvalumab, and bevacizumab, improved progression-free survival in newly diagnosed advanced ovarian cancer.